Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but severe complication of pulmonary embolism (PE), yet its underlying mechanisms remain poorly understood. Peptidyl-prolyl cis/trans isomerase (Pin1), a regulatory enzyme involved in thrombosis, inflammation, and vascular remodeling, may contribute to pulmonary vascular disease.
Macitentan 10 mg and tadalafil 40 mg single-tablet combination therapy (M/T STCT) has been evaluated in the global A DUE study (NCT03904693). Here, we report the results of a subgroup analysis in participants from China.
Pulmonary arterial hypertension (PAH) is a fatal disease with limited available treatments and is characterized by pulmonary vascular remodeling. Substance P (SP) may be involved in vascular remodeling in patients with PAH. However, the underlying mechanism is currently unknown.
Severe diffusion impairment in pulmonary arterial hypertension (PAH), particularly in idiopathic PAH (IPAH), has garnered considerable attention. However, comprehensive data on low diffusion capacity of the lungs for carbon monoxide (DLCO) with preserved lung function remain limited in broader pulmonary hypertension (PH) cohorts.
During the COVID-19 pandemic, Brazil was one of the most affected countries. Patients presented higher risk of acute venous thromboembolism (VTE), in particular, pulmonary embolism (PE).
The American Lung Association and Pulmonary Hypertension Association convened a scientific roundtable of pulmonary hypertension experts to discuss the latest recommendations from the European Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension (PH) and from the 7th World Symposium on Pulmonary Hypertension (WSPH).
This PVRI Digital Webinar is part of the 'Cutting Edge Innovation in Clinical & Experimental PH'session. Features:
A brief introduction to clinical features of PH in BPD - Steve Abman, University of Colorado BPD-associated PH: Current evaluation and therapies - Anne Hilgendorff, Carl von Ossietzky University Oldenburg
BPD-PH: Understudied and undertreated- the need for novel interventions - Bernard Thebaud, Ottawa Hospital Research Institute
Challenges in designing and implementing multicenter trials: A real world perspective on studies of preterm infants - Victoria Niklas,Oak Hills Bio
Pulmonary arterial hypertension (PAH) significantly impacts mortality and quality of life. Access to specialized care may differ between urban and rural patients, potentially influencing outcomes. This study compared the clinical course and treatment patterns of PAH patients from urban and rural settings treated at a single comprehensive care center.
Pulmonary hypertension due to interstitial lung disease (PH-ILD) is associated with high morbidity and mortality. Real-world patients initiating inhaled treprostinil are not well-characterized.
Patients with Eisenmenger syndrome (ES) are at increased risk of thrombotic events, especially in pulmonary vessels. However, both the prevalence and risk factors of pulmonary arterial thrombosis (PAT) have been varied greatly. In this study we sought to examine the prevalence of PAT in adult patients with ES and to identify risk factors.
